Background
FAK structure and activation
Molecular structure of FAK
The mechanism and regulation of FAK activation
The functions of FAK on tumor cells
Tumor cell proliferation, apoptosis and survival
Cell migration and invasion
Epithelial–mesenchymal transformation
FAK in cancer stem cells
The effects of FAK on tumor-associated cells
Immune cells
Cancer-associated fibroblasts (CAFs)
Endothelial cells (ECs)
Targeting FAK in combination therapies
Name | Alternative names | Target(s) | Cancer types | In vitro | In vivo | References |
---|---|---|---|---|---|---|
VS-6062 | PF-562, 271 | FAK, Pyk2 | Glioma | + | + | [175] |
Colon cancer | + | + | [175] | |||
Breast cancer | + | + | [175] | |||
Pancreatic cancer | + | + | ||||
Prostate cancer | + | + | ||||
Lung cancer | + | + | ||||
Hepatocellular cancer | + | + | [179] | |||
Thyroid tumor | + | + | [180] | |||
B16 | − | + | [181] | |||
Ovarian cancer | + | + | [182] | |||
Ewing sarcoma | + | + | [183] | |||
VS-6063 | Defactinib, PF-04554878 | FAK, Pyk2 | Pancreatic cancer | + | + | |
Lung cancer | + | + | ||||
Prostate cancer | + | + | [188] | |||
Ovarian cancer | + | + | ||||
Esophageal cancer | + | + | [191] | |||
Endometrial cancer | + | + | [192] | |||
BI-853520 | IN10018, ifebemtinib | FAK | Breast cancer | + | + | [193] |
KRAS G12C mutant cancer | + | + | [145] | |||
Pancreatic cancer | + | + | [162] | |||
Ovarian cancer | + | + | ||||
Prostate cancer | + | + | [195] | |||
PF-573228 | PF-228 | FAK | Pancreatic cancer | + | + | [196] |
Glioma | + | − | [56] | |||
Lung cancer | + | − | [197] | |||
TAE226 | NVP-226 | FAK, IGF-IR | Breast cancer | + | + | |
Glioma | + | + | ||||
Esophageal cancer | + | + | ||||
GSK2256098 | – | FAK | Pancreatic cancer | + | − | [204] |
Ovarian cancer | + | − | [205] | |||
PF-431396 | – | FAK, Pyk2 | Pancreatic cancer | + | + | [196] |
Malignant pleural mesothelioma | + | + | [196] | |||
VS-4718 | PND-1186 | FAK, Pyk2 | Breast cancer/ovarian cancer | + | + | [206] |
Pancreatic cancer | − | + | [123] | |||
Y15 | – | FAK | Breast cancer | + | + | [207] |
Lung cancer | + | + | [208] | |||
Y11 | – | FAK | Colon cancer/breast cancer | + | + | |
C4 | – | FAK-VEGFR3 interaction | Breast cancer | + | + | [209] |
R2 | – | FAK-p53 interaction | CRC | + | + | [210] |
Name | Alternative names | Target(s) | Cancer types | Status | Phase | NCT number |
---|---|---|---|---|---|---|
VS-6063 | Defactinib, PF-04554878 | FAK, Pyk2 | Advanced non-hematologic Malignancies | Completed | 1 | NCT00787033 |
Non-hematologic cancer | Completed | 1 | NCT01943292 | |||
NSCLC | Completed | 2 | NCT01951690 | |||
Recurrent skin cancer, squamous cell carcinoma of the skin, stage 0 chronic lymphocytic leukemia, stage I chronic lymphocytic Leukemia | Completed | 2 | NCT00563290 | |||
Ovarian cancer | Completed | 1 | NCT01778803 | |||
Solid tumor, pancreatic cancer | Completed | 1 | NCT02546531 | |||
NSCLC, low grade serous ovarian cancer, endometrioid carcinoma, pancreatic cancer | Recruiting | 1 | NCT03875820 | |||
Metastatic uveal melanoma | Recruiting | 2 | NCT04720417 | |||
Pancreas cancer | Recruiting | 2 | NCT04331041 | |||
Ovarian cancer | Recruiting | 1 2 | NCT03287271 | |||
PDAC | Recruiting | 2 | NCT03727880 | |||
Advanced lymphoma, advanced malignant solid neoplasm, hematopoietic and lymphoid cell neoplasm, refractory lymphoma, refractory malignant solid neoplasm, refractory plasma cell myeloma | Active, not recruiting | 2 | NCT04439331 | |||
Glioma | Not yet recruiting | Early 1 | NCT05798507 | |||
Malignant pleural mesothelioma | Terminated | 2 | NCT02004028 | |||
CRC | Terminated | Early 1 | NCT00835679 | |||
Relapsed malignant mesothelioma | Terminated | 1 | NCT02372227 | |||
NSCLC, mesothelioma, pancreatic neoplasms | Unknown status | 1 2 | NCT02758587 | |||
BI 853520 | IN10018, ifebemtinib | FAK | Neoplasms | Completed | 1 | NCT01335269 |
Gastric cancer | Completed | 1 | NCT05327231 | |||
Metastatic melanoma | Recruiting | 1 | NCT04109456 | |||
Pancreatic cancer | Recruiting | 1 2 | NCT05827796 | |||
Platinum-resistant ovarian cancer | Recruiting | 1 2 | NCT05551507 | |||
Locally advanced or metastatic solid tumor | Active, not recruiting | 1 2 | NCT05830539 | |||
Solid tumor | Not yet recruiting | 1 2 | NCT05379946 | |||
GSK2256098 | – | FAK | Solid tumor | Completed | 1 | NCT01138033 |
Cancer | Completed | 1 | NCT00996671 | |||
Pancreatic cancer, adenocarcinoma | Completed | 2 | NCT02428270 | |||
Advanced solid tumor | Completed | 1 | NCT01938443 | |||
Intracranial meningioma, recurrent meningioma, Nf2 gene mutation | Recruiting | 2 | NCT02523014 | |||
VS-4718 | PND-1186 | FAK, Pyk2 | Pancreatic cancer | Terminated | 1 | NCT02651727 |
Non-hematologic cancer, metastatic cancer | Terminated | 1 | NCT01849744 | |||
Relapsed or refractory acute myeloid leukemia, relapsed or refractory B-cell acute lymphoblastic leukemia | Withdrawn | 1 | NCT02215629 | |||
CT-707 | Conteltinib | FAK, ALK, Pyk2 | Advanced pancreatic cancer | Recruiting | 1 2 | NCT05580445 |
NSCLC | Unknown status | 1 | NCT02695550 | |||
VS-6062 | PF-00562271 | FAK, Pyk2 | Head and neck neoplasm, prostatic neoplasm, pancreatic neoplasm | Completed | 1 | NCT00666926 |
AMP-945 | Narmafotinib | FAK | PDAC | Recruiting | 1 2 | NCT05355298 |
APG-2449 | – | FAK, ALK, ROS1 | Advanced solid cancer, NSCLC, esophageal cancer, ovarian cancer, malignant pleural mesothelioma | Recruiting | 1 | NCT03917043 |
Name | Alternative names | Target(s) | Combination agents | Preclinical trials | Clinical trials | ||
---|---|---|---|---|---|---|---|
Cancer types | References | Cancer types | NCT number | ||||
VS-6063 | Defactinib, PF-04554878 | FAK, Pyk2 | Pembrolizumab (a PD1 inhibitor) | – | – | NSCLC, mesothelioma, pancreatic tumor | NCT02758587 |
– | – | PDAC | NCT03727880 | ||||
– | – | Solid tumor, PDAC | NCT02546531 | ||||
VS-6766 (a RAF/MEK inhibitor) | – | – | NSCLC, ovarian cancer, endometrioid carcinoma, pancreatic cancer | NCT03875820 | |||
– | – | Metastatic uveal melanoma | NCT04720417 | ||||
Paclitaxel | Ovarian cancer | [189] | Ovarian cancer | NCT01778803 | |||
Pancreatic cancer | [156] | Ovarian cancer | NCT03287271 | ||||
Gemcitabine | Lung cancer | [185] | Solid tumor, pancreatic cancer | NCT02546531 | |||
VS-5584 NCT00835679 (a PI3K inhibitor) | – | – | Relapsed malignant mesothelioma | NCT02372227 | |||
Radiation therapy | Pancreatic cancer | [184] | Pancreas cancer | NCT04331041 | |||
Cetuximab | – | – | CRC | NCT00835679 | |||
BRD4 inhibitor | lung cancer | [186] | – | – | |||
EGFR-TKI | Lung cancer | [187] | – | – | |||
Docetaxel | Prostate cancer | [188] | – | – | |||
BI 853520 | IN10018, ifebemtinib | FAK | Albumin-bound paclitaxel, gemcitabine, KN046 | – | – | Pancreatic cancer | NCT05827796 |
Cobimetinib, atezolizumab | – | – | Metastatic melanoma | NCT04109456 | |||
PLD | – | – | Platinum-resistant ovarian cancer | NCT05551507 | |||
PLD, toripalimab | – | – | Locally advanced or metastatic solid tumor | NCT05830539 | |||
Docetaxel | – | – | Gastric cancer | NCT05327231 | |||
D-1553 | – | – | Solid tumor | NCT05379946 | |||
KRAS G12C inhibitors | CRC, pancreatic cancer, NSCLC | [145] | – | – | |||
Radiation therapy | Pancreatic cancer | [162] | – | – | |||
Paclitaxel | Ovarian cancer | [194] | – | – | |||
VS-6062 | PF-562,271 | FAK, Pyk2 | Gemcitabine | Pancreatic cancer | [112] | – | – |
Sunitinib | Hepatocellular cancer | [179] | – | – | |||
anti-VEGF | Ovarian cancer | [182] | – | – | |||
AZD-1152 | Ewing sarcoma | [183] | – | – | |||
VS-4718 | PND-1186 | FAK, Pyk2 | Nab-paclitaxel, gemcitabine | – | – | Pancreatic cancer | NCT02651727 |
Gemcitabine, adoptive cell transfer (ACT), Anti-PD1/anti-CTLA4 | Pancreatic cancer | [123] | – | – | |||
GSK2256098 | – | FAK | Trametinib (a MEK inhibitor) | – | – | Advanced solid tumor | NCT01938443 |
Pazopanib | Ovarian cancer | [205] | – | – | |||
CT-707 | Conteltinib | FAK, ALK, Pyk2 | Toripalimab, gemcitabine | – | – | Advanced pancreatic cancer | NCT05580445 |
TAE226 | NVP-226 | FAK, IGF-IR | Radiation therapy | Glioma | [201] | – | – |